Skip to content
DataLookout
Menu

NCT03800693

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 5, 2026 to Aug 5, 2027 Show 5 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Study completion pushed from Sep 17, 2026 to Sep 17, 2028
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 3 of 3 sites
    • Collaborators: details revised at 1 of 2 entries
  2. Notable Primary completion date: Sep 17, 2025 to Aug 5, 2026v14
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Dec 31, 2024 to Sep 17, 2025
    • Study completion date: Dec 31, 2024 to Sep 17, 2026
    • Site details revised at 3 of 3 sites
    v13
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Nov 4, 2024 to Dec 31, 2024
    • Site details revised at 3 of 3 sites
    v12
  5. Minor Site contacts updated at 3 of 3 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Primary and study completion dates pushed to Nov 4, 2024v10
  2. Notable Primary completion date: Nov 4, 2022 to Nov 4, 2023
    • Study completion date: Mar 31, 2023 to Mar 31, 2024
    v9
  3. Minor Site contacts updated at 1 of 3 sitesv8
  4. Notable Primary completion date: Mar 31, 2021 to Nov 4, 2022v7
  5. Minor Site contacts updated at 3 of 3 sitesv6
  6. Notable Eligibility criteria expanded, about 2 wordsv5
  7. Notable Eligibility criteria expanded, about 30 words
    • Site contacts updated at 2 of 3 sites
    v4
  8. Minor Study sites: 1 to 3v3
  9. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 31, 2022 to Mar 31, 2021
    • Study completion date: Jan 31, 2024 to Mar 31, 2023
    • Start date changed from estimate of Jan 1, 2020 to Mar 14, 2019
    • Site details revised
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale
Timeframe: Baseline up to 60 days (course 4)

Secondary (5)

Maximum concentrations achieved (Cmax)
Changes in tumor size
Duration of therapy
Dose density
Frequency of dose holds or reductions

Arms and interventions

2-hour infusion groupActive comparator

Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

6-hour infusion groupExperimental

Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Drugs: Fluorouracil, Leucovorin, Oxaliplatin

Sites

3 sites in 1 country